skip to content

Institute of Metabolic Science

Metabolic Research Laboratories
 

Research Focus

Hannah’s role involves the day-to-day running of an in vivo metabolic phenotyping core service team of technicians. This covers a variety of duties from basic human resources tasks, schedule management and operations, to logistical organisation of experiments, procurement, financial monitoring and budgeting. Hannah is required to liaise with a wide range of people, such as customers (internal and external researchers), facility managers, specialist equipment manufacturers and service providers, Clinical School HR and departmental administration. 

Background and experience

Hannah has worked in a variety of in vivo research settings. Prior to her current role, Hannah spent 5 years working in children’s cancer research both in the UK and Australia. Hannah joined IMS-MRL to stay in science but also to develop her leadership and management skills. Since joining the Disease Model Core (DMC), she has completed her ILM Level 3 and an Associate Project Management apprenticeship. 

Working at the IMS-MRL

Hannah has currently been involved in managing a team restructure to improve operations. Hannah has also been piloting a process with James Warner to improve the communication and transfer of samples from in vivo studies to the Histology Core. Hannah enjoys the opportunity to work with the central admin team and numerous research groups supporting different areas of research, whilst learning new skills related to finance, human resources and procurement. Outside of work, she enjoys basketball, running, reading and growing vegetables. 

Publications

Key publications: 

Poon E. et al (2020) Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven Neuroblastoma, The Journal of Clinical Investigation 

Brierley et al. (2020) Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy, Diabetes 2020;69(11):2481–2489 

Huynh T. et al. (2019) CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth, Biochemical Pharmocology 

Yogev O. et al. (2019) In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis, Cancer Research 

Disease Model Core (DMC) Manager

Contact Details

Email address: 
Classifications: